It is interesting to note that PIV3 vaccine candidates have been extensively evaluated after lumenal airway delivery in adults and infants as young as 3 mo [42]; an age of CF patients in which CFTR replacement would be desirable. The gene discussed is CFTR; the disease is cystic fibrosis.